| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Short Communication |
¶||
From the Department of Pathology,*
Brigham and Women’s
Hospital, Boston, Massachusetts; the Department of
Pathology,
Children’s Hospital, Boston,
Massachusetts; the Department of Pediatric
Oncology,¶
Dana-Farber Cancer Institute, Boston,
Massachusetts; the Departments of
Pathology
and
Pediatrics,||
Harvard Medical School, Boston,
Massachusetts; and Kochi Medical School,
Okohcho, Nankoku, Kochi, Japan
Translocation t(15;19)(q13;p13.1) defines a lethal midline carcinoma arising adjacent to respiratory tract in young people. To characterize molecular alterations responsible for the distinctly aggressive biological behavior of this cancer, we mapped the chromosome 15 and 19 translocation breakpoints by fluorescence in situ hybridization (FISH) and Southern blotting. To evaluate preliminarily the frequency, anatomical distribution, and histological features of t(15;19) cancer, we developed a FISH assay for paraffin sections. Our findings reveal a novel oncogenic mechanism in which the chromosome 19 translocation breakpoint interrupts the coding sequence of a bromodomain gene, BRD4. These studies implicate BRD4 as a potential partner in a t(15;19)-associated fusion oncogene. In addition, we localized the chromosome 15 breakpoint to a 9-kb region in each of two cases, thereby identifying several candidate oncogenes which might represent the BRD4 fusion partner. FISH evaluation of 13 pediatric carcinomas revealed t(15;19) in one of four sinonasal carcinomas, whereas this translocation was not detected in thymic (n = 3), mucoepidermoid (n = 3), laryngeal (n = 2), or nasopharyngeal (n = 1) carcinomas. Our studies shed light on the oncogenic mechanism underlying t(15;19) and provide further evidence that this highly lethal cancer arises from respiratory mucosa.
This article has been cited by other articles:
 |
|
 |
|
  Y. Nakamura, T. Umehara, K. Nakano, M. K. Jang, M. Shirouzu, S. Morita, H. Uda-Tochio, H. Hamana, T. Terada, N. Adachi, et al. Crystal Structure of the Human BRD2 Bromodomain: INSIGHTS INTO DIMERIZATION AND RECOGNITION OF ACETYLATED HISTONE H4 J. Biol. Chem., February 9, 2007; 282(6): 4193 - 4201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ottinger, T. Christalla, K. Nathan, M. M. Brinkmann, A. Viejo-Borbolla, and T. F. Schulz Kaposi's Sarcoma-Associated Herpesvirus LANA-1 Interacts with the Short Variant of BRD4 and Releases Cells from a BRD4- and BRD2/RING3-Induced G1 Cell Cycle Arrest J. Virol., November 1, 2006; 80(21): 10772 - 10786. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. French, J. L. Kutok, W. C. Faquin, J. A. Toretsky, C. R. Antonescu, C. A. Griffin, V. Nose, S. O. Vargas, M. Moschovi, F. Tzortzatou-Stathopoulou, et al. Midline Carcinoma of Children and Young Adults With NUT Rearrangement J. Clin. Oncol., October 15, 2004; 22(20): 4135 - 4139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Westmoreland, J. R. Marks, J. A. Olson Jr., E. M. Thompson, M. A. Resnick, and C. B. Bennett Cell Cycle Progression in G1 and S Phases Is CCR4 Dependent following Ionizing Radiation or Replication Stress in Saccharomyces cerevisiae Eukaryot. Cell, April 1, 2004; 3(2): 430 - 446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Varella-Garcia Molecular Cytogenetics in Solid Tumors: Laboratorial Tool for Diagnosis, Prognosis, and Therapy Oncologist, February 1, 2003; 8(1): 45 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. French, I. Miyoshi, I. Kubonishi, H. E. Grier, A. R. Perez-Atayde, and J. A. Fletcher BRD4-NUT Fusion Oncogene: A Novel Mechanism in Aggressive Carcinoma Cancer Res., January 15, 2003; 63(2): 304 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Sandberg Translocations in Malignant Tumors Am. J. Pathol., December 1, 2001; 159(6): 1979 - 1980. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
